UBS Downgrade Johnson & Johnson [JNJ]. What else is Wall St. saying?

Johnson & Johnson [NYSE: JNJ] gained 0.71% on the last trading session, reaching $148.60 price per share at the time. The company report on August 5, 2020 that Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine.

Company working to ensure broad global access to COVID-19 vaccine candidate, following approval from regulators .

Johnson & Johnson (NYSE: JNJ) (the Company) today announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in the U.S. of 100 million doses of Janssen’s SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the United States following approval or Emergency Use Authorization by the U.S. Food and Drug Administration (FDA).

Johnson & Johnson represents 2.63 billion in outstanding shares, while the company has a total market value of $388.47 billion with the latest information. JNJ stock price has been found in the range of $147.15 to $148.65.

If compared to the average trading volume of 6.87M shares, JNJ reached a trading volume of 3631389 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Johnson & Johnson [JNJ]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for JNJ shares is $166.06 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on JNJ stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

UBS have made an estimate for Johnson & Johnson shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on April 28, 2020. While these analysts kept the previous recommendation, BofA/Merrill raised their target price from $150 to $175. The new note on the price target was released on April 22, 2020, representing the official price target for Johnson & Johnson stock. Previously, the target price had yet another raise to $163, while Citigroup analysts kept a Buy rating on JNJ stock.

The Average True Range (ATR) for Johnson & Johnson is set at 2.22, with the Price to Sales ratio for JNJ stock in the period of the last 12 months amounting to 4.83. The Price to Book ratio for the last quarter was 6.21, with the Price to Cash per share for the same quarter was set at 7.32. Price to Free Cash Flow for JNJ in the course of the last twelve months was 53.36 with Quick ratio for the last quarter at 1.00.

Trading performance analysis for JNJ stock

Johnson & Johnson [JNJ] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.95. With this latest performance, JNJ shares gained by 4.29% in over the last four-week period, additionally sinking by -2.17% over the last 6 months – not to mention a rise of 12.85% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for JNJ stock in for the last two-week period is set at 55.71, with the RSI for the last a single of trading hit 60.08, and the three-weeks RSI is set at 56.27 for Johnson & Johnson [JNJ]. The present Moving Average for the last 50 days of trading for this stock 145.31, while it was recorded at 147.82 for the last single week of trading, and 142.56 for the last 200 days.

Johnson & Johnson [JNJ]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Johnson & Johnson [JNJ] shares currently have an operating margin of +26.24 and a Gross Margin at +66.95. Johnson & Johnson’s Net Margin is presently recorded at +18.41.

Return on Total Capital for JNJ is now 24.16, given the latest momentum, and Return on Invested Capital for the company is 17.37. Return on Equity for this stock inclined to 25.36, with Return on Assets sitting at 9.73. When it comes to the capital structure of this company, Johnson & Johnson [JNJ] has a Total Debt to Total Equity ratio set at 48.23. Additionally, JNJ Total Debt to Total Capital is recorded at 32.54, with Total Debt to Total Assets ending up at 18.18. Long-Term Debt to Equity for the company is recorded at 45.75, with the Long-Term Debt to Total Capital now at 30.87.

Reflecting on the efficiency of the workforce at the company, Johnson & Johnson [JNJ] managed to generate an average of $114,365 per employee. Receivables Turnover for the company is 5.75 with a Total Asset Turnover recorded at a value of 0.53.Johnson & Johnson’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.20.

Johnson & Johnson [JNJ]: An earnings per share (EPS) analysis

With the latest financial reports released by the company, Johnson & Johnson posted 2.12/share EPS, while the average EPS was predicted by analysts to be reported at 2.01/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 5.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for JNJ. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Johnson & Johnson go to 5.08%.

An analysis of insider ownership at Johnson & Johnson [JNJ]

There are presently around $273,322 million, or 70.70% of JNJ stock, in the hands of institutional investors. The top three institutional holders of JNJ stocks are: VANGUARD GROUP INC with ownership of 233,816,138, which is approximately 2.417% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 192,545,915 shares of the stock with an approximate value of $28.61 billion in JNJ stocks shares; and STATE STREET CORP, currently with $22.52 billion in JNJ stock with ownership of nearly -0.086% of the company’s market capitalization.

Positions in Johnson & Johnson stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 1,460 institutional holders increased their position in Johnson & Johnson [NYSE:JNJ] by around 90,445,453 shares. Additionally, 1,339 investors decreased positions by around 73,141,640 shares, while 259 investors held positions by with 1,675,723,686 shares. The mentioned changes placed institutional holdings at 1,839,310,779 shares, according to the latest SEC report filing. JNJ stock had 113 new institutional investments in for a total of 6,121,161 shares, while 110 institutional investors sold positions of 9,921,835 shares during the same period.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on skype
Skype
Share on reddit
Reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam